Treatment of unresectable hepatocellular carcinoma

Keith Stuart; J. Nicolas Vauthey; Robert de W. Marsh; Gary L. Davis; Chet R. Rees; Henri Bismuth; Didier Samuel; Luc Engerran; Jean Claude Trinchet; Sylvie Chevret; Didier Mathieu

doi:10.1056/NEJM199509283331313

Treatment of unresectable hepatocellular carcinoma

Keith Stuart, J. Nicolas Vauthey, Robert de W. Marsh, Gary L. Davis, Chet R. Rees, Henri Bismuth, Didier Samuel, Luc Engerran, Jean Claude Trinchet, Sylvie Chevret, Didier Mathieu

Research output: Contribution to journal › Letter › peer-review

5 Scopus citations

Abstract

To the Editor: In a group of patients with unresectable hepatocellular carcinoma but without severe liver disease, Trinchet et al. (May 11 issue)¹ found that chemoembolization with Lipiodol (iodized oil) reduced tumor growth, often caused acute liver failure, and did not significantly improve survival. Because of variations in protocols and in the levels of expertise with which chemoembolization is performed, the authors' conclusion that this therapy should not be recommended may not be applicable to many patients. Regardless of the exact method used, there will be some degree of hepatic damage after embolization, and this accumulated injury following repeated chemoembolizations.

Original language	English (US)
Pages (from-to)	877-878
Number of pages	2
Journal	New England Journal of Medicine
Volume	333
Issue number	13
DOIs	https://doi.org/10.1056/NEJM199509283331313
State	Published - Sep 28 1995
Externally published	Yes

ASJC Scopus subject areas

General Medicine

Access to Document

10.1056/NEJM199509283331313

Cite this

@article{0a36409fda5f4f589ce93166fb3f3441,

title = "Treatment of unresectable hepatocellular carcinoma",

abstract = "To the Editor: In a group of patients with unresectable hepatocellular carcinoma but without severe liver disease, Trinchet et al. (May 11 issue)1 found that chemoembolization with Lipiodol (iodized oil) reduced tumor growth, often caused acute liver failure, and did not significantly improve survival. Because of variations in protocols and in the levels of expertise with which chemoembolization is performed, the authors' conclusion that this therapy should not be recommended may not be applicable to many patients. Regardless of the exact method used, there will be some degree of hepatic damage after embolization, and this accumulated injury following repeated chemoembolizations.",

author = "Keith Stuart and Vauthey, {J. Nicolas} and Marsh, {Robert de W.} and Davis, {Gary L.} and Rees, {Chet R.} and Henri Bismuth and Didier Samuel and Luc Engerran and Trinchet, {Jean Claude} and Sylvie Chevret and Didier Mathieu",

year = "1995",

month = sep,

day = "28",

doi = "10.1056/NEJM199509283331313",

language = "English (US)",

volume = "333",

pages = "877--878",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "13",

}

TY - JOUR

T1 - Treatment of unresectable hepatocellular carcinoma

AU - Stuart, Keith

AU - Vauthey, J. Nicolas

AU - Marsh, Robert de W.

AU - Davis, Gary L.

AU - Rees, Chet R.

AU - Bismuth, Henri

AU - Samuel, Didier

AU - Engerran, Luc

AU - Trinchet, Jean Claude

AU - Chevret, Sylvie

AU - Mathieu, Didier

PY - 1995/9/28

Y1 - 1995/9/28

N2 - To the Editor: In a group of patients with unresectable hepatocellular carcinoma but without severe liver disease, Trinchet et al. (May 11 issue)1 found that chemoembolization with Lipiodol (iodized oil) reduced tumor growth, often caused acute liver failure, and did not significantly improve survival. Because of variations in protocols and in the levels of expertise with which chemoembolization is performed, the authors' conclusion that this therapy should not be recommended may not be applicable to many patients. Regardless of the exact method used, there will be some degree of hepatic damage after embolization, and this accumulated injury following repeated chemoembolizations.

AB - To the Editor: In a group of patients with unresectable hepatocellular carcinoma but without severe liver disease, Trinchet et al. (May 11 issue)1 found that chemoembolization with Lipiodol (iodized oil) reduced tumor growth, often caused acute liver failure, and did not significantly improve survival. Because of variations in protocols and in the levels of expertise with which chemoembolization is performed, the authors' conclusion that this therapy should not be recommended may not be applicable to many patients. Regardless of the exact method used, there will be some degree of hepatic damage after embolization, and this accumulated injury following repeated chemoembolizations.

UR - http://www.scopus.com/inward/record.url?scp=0029653630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029653630&partnerID=8YFLogxK

U2 - 10.1056/NEJM199509283331313

DO - 10.1056/NEJM199509283331313

M3 - Letter

C2 - 7651488

AN - SCOPUS:0029653630

SN - 0028-4793

VL - 333

SP - 877

EP - 878

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 13

ER -

Treatment of unresectable hepatocellular carcinoma

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this